Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
175 USD | -0.49% | +3.15% | -11.45% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With an expected P/E ratio at 32.3 and 29.12 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.92% | 80.23B | B+ | ||
+24.38% | 3.68B | B- | ||
+2.23% | 3.27B | B- | ||
+12.67% | 1.67B | - | ||
-3.52% | 1.28B | - | ||
-26.65% | 1.22B | B | ||
-28.50% | 1.19B | C- | ||
-19.43% | 1.05B | - | ||
-9.88% | 943M | - | ||
-1.49% | 915M | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZTS Stock
- Ratings Zoetis Inc.